News

Chris Smith, COO of IQVIA Biotech, discusses with Moe Alsumidaie how large CROs are responding to EBP targets.

Peter O'Donnell writes about the results of a public opinion survey, the latest the European drug industry's attempts to fight back against what it sees as a climate of misunderstanding.

Tony Fiorino, Chief Medical Officer of electroCore, discusses challenges he has faced with device studies, and will elaborate on his experiences about the differences between device and drug trials.

A trial’s success depends on enrolling the planned number of patients in the shortest possible time frame. Such thinking can insight a limited focus on obtaining and analyzing all investigator site enrollment data - as if that would solve all problems pertaining to site enrollment performance, writes Gen Li, President of Phesi.

Bill Tobia, CEO of Clinstruct, Ahmed Bouzid, CEO, Witlingo, and Brielle Nickoloff, Lead Product Marketing, Witlingo, discuss how voice will change the clinical research paradigm.

Penelope Manasco, CEO of MANA UBM, disputes recommendations made by the original authors she finds to be problematic and worthy of further discussion.